Spots Global Cancer Trial Database for TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: TTX-030 in Combination With Immunotherapy and/or Chemotherapy in Subjects With Advanced Cancers
Official Title: Phase 1/1b Study to Evaluate the Safety and Activity of TTX-030 (Anti-CD39) in Combination With Pembrolizumab or Budigalimab and/or Chemotherapy in Subjects With Advanced Solid Tumors
Study ID: NCT04306900
Conditions
Study Description
Brief Summary: This is a phase 1/1b study of TTX-030 in combination therapy, an antibody that inhibits CD39 enzymatic activity, leading to accumulation of pro-inflammatory adenosine triphosphate (ATP) and reduction of immunosuppressive adenosine, which may change the tumor microenvironment and promote anti-tumor immune response. This trial will study the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TTX-030 in combination with immunotherapy and/or standard chemotherapies.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
HonorHealth Research Institute, Scottsdale, Arizona, United States
City of Hope Medical Center Clinical Trials Office, Duarte, California, United States
University of Southern California, Los Angeles, California, United States
Cedars-Sinai Medical Center, Los Angeles, California, United States
UCLA Hematology/Oncology, Los Angeles, California, United States
Chao Family Comprehensive CC, UCI, Orange, California, United States
UC Davis Comprehensive Cancer Center, Sacramento, California, United States
Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida, United States
Ocala Oncology Center PL, Ocala, Florida, United States
Orlando Health UF Health Cancer Center, Orlando, Florida, United States
IACT Health - John B. Amos Cancer Center, Columbus, Georgia, United States
University of Chicago Medical Center, Chicago, Illinois, United States
Norton Cancer Institute, Louisville, Kentucky, United States
Ochsner Medical Center, New Orleans, Louisiana, United States
Nebraska Cancer Center Oncology Hematology West P.C., Omaha, Nebraska, United States
Montefiore Medical Center, Bronx, New York, United States
University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
University of Toledo, Toledo, Ohio, United States
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Prisma-Health Cancer Institute, Greenville, South Carolina, United States
West Cancer Center and Research Institute, Germantown, Tennessee, United States
Sarah Cannon Research Institute, Nashville, Tennessee, United States
NEXT Oncology, San Antonio, Texas, United States
Hunstman Cancer Intitute, Salt Lake City, Utah, United States
Virginia Cancer Specialists, Fairfax, Virginia, United States
Froedtert Hospital & Medical College of Wisconsin, Milwaukee, Wisconsin, United States
National Cancer Center, Seogu, Busan, Korea, Republic of
National Cancer Center, Ilsandong-gu, Goyang-si, Gyeonggi-do, Korea, Republic of
Seoul National University, Seongnam-si Bundan-gu, Kyunggi-do, Korea, Republic of
Samsung Medical Center, Gangnam-gu, Seoul, Korea, Republic of
Severance Hospital Yonsei University, Seodaemun-gu, Seoul, Korea, Republic of
Asan Medical Center, Songpa-gu, Seoul, Korea, Republic of
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
